ERBB3 and neoplasm: In a preclinical study, patritumab deruxtecan significantly sensitized the tumor to PD-1 blockade, which further suggests patritumab deruxtecan is a promising candidate as a partner of immunotherapy for patients with tumor-specific HER3 expression [185].